Bio Usawa, a company focused on producing life-saving, affordable monoclonal therapies for Africa and beyond, congratulates Mina Adel, MPH, PMP on his appointment to the WHO Product Development for Vaccines Advisory Committee. Mr. Adel comes to this position from a productive career spanning biologics and vaccine – focused positions with IAVI, WHO, the Egyptian Drug Authority, and the Egyptian Ministry of Health and Population.

In his new position on the WHO Technical Advisory Group, Mr. Adel will be supporting evidence-based decision making in support of achieving healthcare equity in LMIC by:

• Advocating for product designs and manufacturing approaches that enable timely access in LMICs;
• Supporting evidence-aligned product profiles and policy advice that accelerate uptake;
• Fostering collaboration between research, regulatory, and manufacturing stakeholders to strengthen immunization programs and delivery.

Bio Usawa wishes great success to Mr. Adel in our shared Mission to expand access to critical biotherapies on the Continent.